The following government grants in the FederalGrants.com database contain the term National Institutes of Health in the listing.
Grants are sorted newest to oldest. Select a grant title to view the complete details, including information on who to contact and how to apply.
Grant Title | CFDA | Funding Number |
Engaging Men in HIV Testing, Prevention, and Care (R01 Clinical Trial Optional) |
93.242, 93.855 |
PA-19-042 |
Engaging Men in HIV Testing, Prevention, and Care (R21 Clinical Trial Optional) |
93.242, 93.855 |
PA-19-050 |
Accelerating Colorectal Cancer Screening and follow-up through Implementation Science (ACCSIS)(UG3/UH3 Clinical Trial Required) |
93.353, 93.394 |
RFA-CA-19-018 |
New Research Directions that Advance the NHLBI Strategic Vision Normal Biology (R21 - Clinical Trial Not Allowed) |
93.233, 93.837, 93.838, 93.839, 93.840 |
PA-19-049 |
NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01 - Clinical Trial Not Allowed) |
93.233, 93.837, 93.838, 93.839 |
PAR-19-048 |
Human Islet Research Network - Consortium on Targeting and Regeneration (HIRN-CTAR) (U01 Clinical Trial Not Allowed) |
93.847 |
RFA-DK-18-014 |
Immuno-Oncology Translation Network (IOTN): Immuno-engineering to Improve Immunotherapy (i3) Centers (U54 Clinical Trial Not Allowed) |
93.286, 93.353, 93.393, 93.395, 93.866 |
RFA-CA-19-013 |
Advancing Research in Augmentative and Alternative Communication (AAC) (R01 Clinical Trial Optional) |
93.173 |
PA-19-047 |
Advancing Research in Augmentative and Alternative Communication (AAC) (R21 Clinical Trial Optional) |
93.173 |
PA-19-046 |
End-of-Life and Palliative Care Approaches to Advanced Signs and Symptoms (R21- Clinical Trial Optional) |
93.361 |
PAR-19-044 |
End-of-Life and Palliative Care Approaches to Advanced Signs and Symptoms (R01 Clinical Trial Optional) |
93.361 |
PAR-19-045 |
Immuno-Oncology Translation Network (IOTN): Cancer Immunotherapy Research Projects (U01 Clinical Trial Not Allowed) |
93.113, 93.121, 93.273, 93.353, 93.853, 93.855 |
RFA-CA-19-015 |
Immuno-Oncology Translation Network (IOTN): Cancer Immunoprevention Research Projects (U01 Clinical Trial Not Allowed) |
93.113, 93.121, 93.353, 93.853 |
RFA-CA-19-014 |
Immuno-Oncology Translation Network (IOTN): Cancer Immunoprevention Research Projects (UG3/UH3) |
93.113, 93.121, 93.353, 93.393, 93.853 |
RFA-CA-19-012 |
Novel Approaches for Relating Genetic Variation to Function and Disease (R43/R44 Clinical Trial Not Allowed) |
93.172 |
PA-19-043 |
Centers on the Demography and Economics of Alzheimer's Disease and Alzheimer's Related Dementias (P30 Clinical Trial Optional) |
93.866 |
RFA-AG-20-002 |
Centers on the Demography and Economics of Aging (P30 Clinical Trial Optional) |
93.866 |
RFA-AG-20-001 |
Demography and Economics of Aging and AD-ADRD Coordinating Center (R24 Clinical Trial Not Allowed) |
93.866 |
RFA-AG-20-003 |
Promoting Research on Music and Health: Phased Innovation Award for Music Interventions (R61/R33 Clinical Trial Optional) |
93.173, 93.213, 93.242, 93.273, 93.853, 93.866 |
RFA-AT-19-001 |
Promoting Research on Music and Health: Fundamentals and Applications (R01 Clinical Trials Optional) |
93.121, 93.173, 93.213, 93.242, 93.273, 93.361, 93.853, 93.867 |
RFA-NS-19-008 |
Promoting Research on Music and Health: Fundamentals and Applications (R21 Clinical Trials Optional) |
93.113, 93.121, 93.173, 93.213, 93.242, 93.268, 93.273, 93.361, 93.853, 93.867 |
RFA-NS-19-009 |
Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed) |
93.242 |
RFA-MH-19-235 |
Lewy Body Dementia Center Without Walls (CWOW) (U54 Clinical Trial Not Allowed) |
93.853, 93.866 |
RFA-NS-19-013 |
Limited Competition: Restoring Research Resources Lost or Damaged Due to Hurricanes Harvey, Irma, and Maria (R24 Clinical Trial Optional) |
93.113, 93.121, 93.172, 93.173, 93.213, 93.242, 93.273, 93.279, 93.286, 93.307, 93.393, 93.394, 93.395, 93.396, 93.399, 93.663, 93.846, 93.853, 93.855, 93.859, 93.865, 93.866, 93.867 |
RFA-OD-18-102 |
Development of Personalized In Vitro Assays to Quantitatively Assess Age-related Changes in Cellular Resiliencies to Physiologic Stressors (R43/R44 Clinical Trial Not Allowed) |
93.866 |
RFA-AG-19-025 |
Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (U01 Clinical Trial Optional) |
93.113, 93.279, 93.846, 93.853, 93.867 |
PAR-19-040 |
Countermeasures Against Chemical Threats (CounterACT): Identification of Therapeutic Lead Compounds (U01 Clinical Trial Not Allowed) |
93.113, 93.279, 93.846, 93.853, 93.867 |
PAR-19-039 |
Limited Competition: Extramural Research Facilities Restoration Program: Hurricanes Harvey, Irma, and Maria Disaster Relief (C06 Clinical Trial Not Allowed) |
93.662 |
PAR-19-041 |
Development of Personalized In Vitro Assays to Quantitatively Assess Age-related Changes in Cellular Resiliencies to Physiologic Stressors (R41/R42 Clinical Trial Not Allowed) |
93.866 |
RFA-AG-19-026 |
Early Screening for Autism Spectrum Disorder (R21 Clinical Trial Not Allowed) |
93.113, 93.173, 93.242, 93.853, 93.865 |
RFA-MH-19-121 |
Emerging Global Leader Award (K43 Independent Clinical Trial Required) |
93.113, 93.121, 93.172, 93.242, 93.313, 93.398, 93.853 |
PAR-19-038 |
Early Screening for Autism Spectrum Disorder (R01 Clinical Trial Not Allowed) |
93.113, 93.173, 93.242, 93.853 |
RFA-MH-19-120 |
Initiative for Maximizing Student Development (IMSD) (T32) |
93.859 |
PAR-19-037 |
Medical Scientist Training Program (T32) |
93.859 |
PAR-19-036 |
NINDS Morris K. Udall Center without Walls for Parkinsons Disease Research (P20 Clinical Trial Optional) |
93.853 |
RFA-NS-18-027 |
NINDS Morris K. Udall Centers of Excellence for Parkinsons Disease Research (P50 Clinical Trial Optional) |
93.853 |
RFA-NS-18-026 |
Reproductive Medicine Collaborative Clinical Trials Program (Collaborative R01 Clinical Trial Required) |
93.865 |
RFA-HD-19-022 |
Commercializing Understudied Proteins from the Illuminating the Druggable Genome Project (IDG) (R41/R42 Clinical Trial Not Allowed) |
93.121, 93.242, 93.350, 93.393, 93.394, 93.395, 93.396, 93.399, 93.879 |
PA-19-033 |
Commercializing Understudied Proteins from the Illuminating the Druggable Genome Project (IDG) (R43/R44 Clinical Trial Not Allowed) |
93.121, 93.242, 93.350, 93.393, 93.394, 93.395, 93.396, 93.399, 93.879 |
PA-19-034 |
NLM Grants for Scholarly Works in Biomedicine and Health (G13 Clinical Trial Not Allowed) |
93.879 |
PAR-19-032 |
Search Results 3921-3960 of 14606 [Prev] 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 [Next] |